References
- Gonzalez-Peralta RG, Jolley CD. Hepatitis C virus. In: Walker WA, Goulet O, Kleinman RE, Sherman PM, Shneider BL and Sanderson IA (eds). Pediatric Gastrointestinal Disease, 4th ed. BC Decker Inc. 2004; 1156-1169.
- Di Ciommo V, Russo P, Rava L, Caprino L. Interferon alpha in the treatment of chronic hepatitis C in children: a metanalysis. J Viral Hepat 2003; 10: 210–214.
- Tabaru A, Narita R, Hiura M, Abe S, Otsuki M. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 2005; 100: 862–867.
- Snyder JD, Pickering LK. Viral hepatitis. In: Behrman ER, Kliegman MR, Jenson BH (eds). Nelson Textbook of Pediatrics, 17th ed. W.B. Saunders Co., Philadelphia, 2004; 1324-1332.
- Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452–1457.
- Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Wollman J, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
- Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610–1615.
- Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G. Treatment of genotype lb HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. New Microbiol 2005; 28: 23–29.
- Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C ? Clin Nephrol 2005; 63: 232–235.
- Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol 2005; 28: 13–21.
- Ebeling F, Lappalainen M, Vuoristo M, Nuutinen H, Leino R, Karvonen AL, et al. Factors predicting interferon treatment response in patients with chronic hepatitis C: late viral clearance does not preclude a sustained response. Am J Gastroenterol 2001; 96: 1237–1242.
- Mamori S, Suzuki F, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. J Gastroenterol 2004; 39: 776–782.
- Russo MW, Brown RS Jr. Should patients with chronic hepatitis C who have normal ALT levels be treated? Curr Gastroenterol Rep 2001; 3: 49–53.
- Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, et al. Interferon alpha-2b and rib-avirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99: 1700-1705.
- Kamar N, Izopet J, Rostaing L. Hepatitis C infection among patients receiving hemodialysis. Nephrologie 2003; 24: 133–141.
- Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon alf a-2b therapy in multitransfused children with beta-tha- lassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis 1999; 18: 709–715.
- Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha- inter-feron in beta-thalassemics with chronic hepatitis C. Blood 1997; 90: 2207–2212.
- Li CK, Chan PK, Ling SC, Ha SY. Interferon and rib-avirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002; 117: 755–758.